Genomics Used to Improve DEpression Decisions (GUIDED)
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Sponsor: Assurex Health Inc.
This NA trial investigates Major Depressive Disorder (MDD) and is currently completed. Assurex Health Inc. leads this study, which shows 14 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
-
Feb 2020 — Jan 2021 [monthly]
Completed NA
Phase: PHASE4 → NA
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Oct 2017 — Mar 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE4
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Assurex Health Inc.
- University of Michigan
For direct contact, visit the study record on ClinicalTrials.gov .